DCM Shriram Ltd

The transcript from the provided pages does not mention any current or planned fundraising through debt or equity. Key points related to capital and finance are: - The company is actively investing in organic and inorganic growth, including acquisitions (Hindustan Specialty Chemicals, DNV Global) and CAPEX on renewable power, aluminum chloride capacity, and Fenesta. - Capital allocation focuses on the chemicals, sugar, ethanol, farm solutions, and Fenesta businesses with a mix of organic and inorganic investments based on need and returns. - No specific mention was made regarding new debt or equity fundraising. - Discussions on corporate restructuring are in progress but no definitive update on financing linked to this is stated. - The company maintains financial discipline with a robust balance sheet supporting agile investments, but no explicit plans for fresh fundraise were disclosed. Therefore, as per available info, no announced current or future fundraising through debt or equity.

- The company made two significant acquisitions: Hindustan Specialty Chemicals and DNV Global Private Limited (hardware space). - Ongoing capex projects include aluminum chloride and calcium chloride capacities at Bharuch. - Additional injection of 6.6 MW of green power at Bharuch, total renewable power availability now 50 MW, and a 68-MW renewable power project in Kota progressing on schedule. - Expansion of Epoxy business capacity is planned, with evaluations underway for technology and capacity increases; Board approval pending. - Focus on growing Farm Solutions and Fenesta businesses with relatively lower capital requirements compared to chemicals and sugar. - Emphasis on both organic and inorganic growth, with capital allocation driven by business needs, growth agenda, and return hurdles. - Compressed biogas plant commissioned in March 2025 is operating at ~90% utilization. - Corporate restructuring under review, with Board approval expected in upcoming months to optimize capital deployment.

- Shriram Farm Solutions aims to expand its product range beyond wheat to include vegetables and other crops for year-round sales, supporting volume growth. - New product launches drive growth; about 20% of FY'25 revenue came from products launched in the last two years. - Chemicals business expects volume-driven growth with operationalization and ramp-up of new projects, including Caustic Soda and downstream products like hydrogen peroxide. - Epoxy market demand expected to grow from 200 kt to 300 kt per annum in 3 years; company plans capacity expansion and export market focus. - Fertilizer demand to remain healthy due to early monsoon and stable subsidy policies. - Fenesta Building Systems targets market expansion supported by aluminum extrusion project and hardware business acquisition. - Overall, capital allocation balances organic and inorganic growth across chemicals, sugar-ethanol, farm solutions, and Fenesta, with aggressive growth ambitions in all.

- The company expects continued volume-driven growth across businesses with operationalization of new projects and capacity ramp-up, especially in Chemicals and Farm Solutions. - Farm Solutions aims to expand its product portfolio beyond wheat/rabi to include vegetables and other crops, targeting year-round sales and growth. - New product launches contribute around 20% of revenues; aggressive R&D investments continue to drive this pipeline. - Growth in plant nutrition and crop protection verticals is a strategic focus to balance revenue growth. - EBITDA and margins are expected to improve, driven by cost efficiencies such as lower power costs in Chemicals and higher captive consumption. - Seasonality implies Q3 and Q4 should improve earnings, aiding to offset any earlier deficits. - Strategic acquisitions and inorganic growth (e.g., Hindustan Specialty, DNV Global) alongside organic CAPEX will support future expansion. - EPS growth is aligned with revenue and margin improvements as capital projects start yielding returns in forthcoming quarters.

- Fenesta Building Systems' order book continues to be healthy as of Q1 FY'26. - No specific figures for the current or expected order book or pending orders were provided in the transcript. - The segment saw revenue growth of 21% year-on-year, indicating strong demand and execution. - Higher fixed expenses and marketing costs suggest ongoing investment to support order book growth and expansion into new adjacencies.